Cancer Pain Pipeline Guide for Drugs in Development 2021 – ResearchAndMarkets.com

Cancer Pain Pipeline Guide for Drugs in Development 2021 – ResearchAndMarkets.com




Cancer Pain Pipeline Guide for Drugs in Development 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cancer Pain (Central Nervous System) – Drugs in Development, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 7, 8, 2, 20, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

The Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Report Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain.
  • The pipeline guide reviews pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Pain therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

     

Key Topics Covered:

  • Cancer Pain – Overview
  • Cancer Pain – Therapeutics Development
  • Cancer Pain – Therapeutics Assessment
  • Cancer Pain – Companies Involved in Therapeutics Development
  • Cancer Pain – Drug Profiles
  • Cancer Pain – Dormant Projects
  • Cancer Pain – Discontinued Products
  • Cancer Pain – Product Development Milestones

Companies Mentioned

  • AfaSci Inc
  • Alexza Pharmaceuticals Inc
  • AngioChem Inc
  • Aphios Corp
  • Aquilus Pharmaceuticals Inc
  • AstraZeneca Plc
  • Beckley Canopy Therapeutics Ltd
  • Bisichem Co Ltd
  • Cassava Sciences Inc
  • Chengdu Easton Biopharmaceuticals Co Ltd
  • Concentric Analgesics Inc
  • Fujimoto Pharmaceutical Corp
  • IACTA Pharmaceuticals Inc
  • Indaptus Therapeutics Inc
  • IntelGenx Corp
  • iX Biopharma Ltd
  • Jiangsu Huatai Chenguang Pharmaceutical Co Ltd
  • Klaria Pharma Holding AB
  • Komipharm International Co Ltd
  • Luye Pharma Group Ltd
  • Medlab Clinical Ltd
  • Mundipharma International Ltd
  • Nanomerics Ltd
  • Neurocentrx Pharma Ltd
  • Nippon Zoki Pharmaceutical Co Ltd
  • Orion Corp
  • Pfizer Inc
  • ProNeurogen Inc
  • Quell Therapeutics Ltd
  • Ribomic Inc
  • Sedor Pharmaceuticals LLC
  • Shandong Boan Biotechnology Co Ltd
  • Sorrento Therapeutics Inc
  • Tetra Bio-Pharma Inc
  • Tris Pharma Inc
  • Virpax Pharmaceuticals Inc
  • WEX Pharmaceuticals Inc
  • Winston Pharmaceuticals Inc
  • Yichang Renfu Pharmaceutical Co Ltd
  • Yongzhan International Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/c1njkz

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900